Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. held its 2026 annual meeting, where stockholders approved several key proposals. These included the re-election of five directors and the ratification of Wolf & Company, P.C. as the independent auditor. Significantly, stockholders approved an amendment to the 2021 Stock Plan, increasing the shares reserved for issuance by 600,000 to a total of 600,061. Additionally, a proposal for a reverse stock split, with a ratio between 1-for-2 and 1-for-20, was approved, granting the Board discretion to implement it within the next year to maintain Nasdaq compliance, though there is no present intention to do so.

Bluejay Diagnostics, Inc. announced the closing of a private placement of its securities, raising approximately $7.7 million in net proceeds after fees and expenses. The offering included pre-funded warrants, Series G warrants, and Series H warrants, with a combined price of $2.324 per unit. H.C. Wainwright & Co. served as the exclusive placement agent. The company intends to use the net proceeds to fund matters related to obtaining FDA approval, including clinical studies, as well as for other research and development activities and general working capital needs. Bluejay has also agreed to file a resale registration statement for the securities issued in the placement.

Bluejay Diagnostics, Inc. announced the closing of a private placement, securing $8.5 million in upfront gross proceeds. The offering involved the sale of 3,655,917 shares of common stock (or pre-funded warrants) and accompanying series G and H warrants, which could generate an additional $15.2 million if fully exercised. The company anticipates these net proceeds will extend its cash runway into the first quarter of 2027, beyond its expected FDA submission, and potentially well beyond FDA approval and first year of commercialization if warrants are fully exercised. The funds will be allocated towards obtaining FDA approval, related clinical studies, other research and development activities, and general working capital needs.

Bluejay Diagnostics, Inc. announced it has entered into definitive agreements for a private placement, expecting to raise $8.5 million in gross proceeds upfront. The offering includes 3,655,917 shares of common stock (or pre-funded warrants) and accompanying Series G and H warrants, with a purchase price of $2.325 per share. The company could receive an additional $15.1 million if the warrants are fully exercised. These funds are projected to extend Bluejay's cash runway into the first quarter of 2027, beyond its expected FDA submission, and will be used for FDA approval processes, research and development, and general working capital.

Bluejay Diagnostics announced a strategic partnership with Argonaut Manufacturing Services to advance its Symphony™ platform. This collaboration aims to establish scalable U.S.-based manufacturing capabilities, strengthen commercial infrastructure, and enhance supply chain resilience. The partnership is crucial for supporting Bluejay's ongoing clinical development programs and future commercialization objectives for its near-patient diagnostic solutions, particularly the IL-6 Test for sepsis.

Bluejay Diagnostics reported a net loss of $(1.92) million for Q1 2026, an increase from $(1.86) million in Q1 2025, with cash and cash equivalents decreasing to $3.68 million. The company issued a going concern warning, stating current cash resources will fund operations only through Q3 2026 and requires at least $20 million by the end of 2027. Despite financial challenges, Bluejay is progressing with its SYMON-II clinical study for the Symphony IL-6 test, having enrolled approximately 680 of 750 target patients.

Bluejay Diagnostics provided a corporate update for Q1 2026, highlighting significant progress in its Symphony program. The company continued strong enrollment in the SYMON-II pivotal clinical study, reaching approximately 680 out of 750 target patients. Manufacturing readiness for Symphony cartridges advanced with technical issues resolved, and the company is progressing towards regulatory submission. As of March 31, 2026, Bluejay reported $3.7 million in cash and cash equivalents and a net loss of $1.9 million for the quarter.

Bluejay Diagnostics provided a corporate update for Q1 2026, highlighting significant progress in its Symphony near-patient diagnostic platform. The company continued strong enrollment in its SYMON-II pivotal clinical study, reaching approximately 680 out of 750 target patients, and advanced manufacturing readiness for Symphony cartridges. Bluejay also maintained its objective for a future FDA 510(k) submission for its Symphony IL-6 test. Financially, the company reported $3.7 million in cash and cash equivalents and a net loss of $1.9 million for Q1 2026, consistent with the prior year.

Bluejay Diagnostics, Inc. announced its Annual Meeting of Stockholders to be held on June 9, 2026. Stockholders will vote on several key proposals, including the election of five Board nominees and the ratification of Wolf & Company, P.C. as the independent auditor for 2026. Additionally, significant proposals include approving an amendment to effect a reverse stock split of the Company's common stock and increasing the number of shares available for issuance under the 2021 Stock Plan by 600,000 shares.

Bluejay Diagnostics issued a press release on April 7, 2026, providing an update on the status of patient enrollment in its ongoing SYMON-II clinical trial. This update is relevant to investors as it provides insight into the progress of a key clinical trial for the company.